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Abstract
Background: Frailty has been associated with worse prognosis following COVID-19 infection. While several studies
have reported the association between frailty and COVID-19 mortality or length of hospital stay, there have been no
community-based studies on the association between frailty and risk of severe infection. Considering that different
definitions have been identified to assess frailty, this study aimed to compare the association between frailty and
severe COVID-19 infection in UK Biobank using two frailty classifications: the frailty phenotype and the frailty index.
Methods: A total of 383,845 UK Biobank participants recruited 2006–2010 in England (211,310 [55.1%] women, baseline
age 37–73 years) were included. COVID-19 test data were provided by Public Health England (available up to 28 June
2020). An adapted version of the frailty phenotype derived by Fried et al. was used to define frailty phenotype (robust,
pre-frail, or frail). A previously validated frailty index was derived from 49 self-reported questionnaire items related to
health, disease and disability, and mental wellbeing (robust, mild frailty, and moderate/severe frailty). Both classifications
were derived from baseline data (2006–2010). Poisson regression models with robust standard errors were used to
analyse the associations between both frailty classifications and severe COVID-19 infection (resulting in hospital
admission or death), adjusted for sociodemographic and lifestyle factors.
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Results: Of UK Biobank participants included, 802 were admitted to hospital with and/or died from COVID19 (323
deaths and 479 hospitalisations). After analyses were adjusted for sociodemographic and lifestyle factors, a higher risk
of COVID-19 was observed for pre-frail (risk ratio (RR) 1.47 [95% CI 1.26; 1.71]) and frail (RR 2.66 [95% CI 2.04; 3.47])
individuals compared to those classified as robust using the frailty phenotype. Similar results were observed when the
frailty index was used (RR mildly frail 1.46 [95% CI 1.26; 1.71] and RR moderate/severe frailty 2.43 [95% CI 1.91; 3.10]).
Conclusions: Frailty was associated with a higher risk of severe COVID-19 infection resulting in hospital admission or
death, irrespective of how it was measured and independent of sociodemographic and lifestyle factors. Public health
strategies need to consider the additional risk that COVID-19 poses in individuals with frailty, including which additional
preventive measures might be required.
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Background
Since January 2020, COVID-19—the disease generated by
the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)—has reached pandemic status due to its in-
fectivity and fatality [1, 2]. Globally, more than 43 million
people have been infected with the virus, and more than 1
million have died from it up to the end of October 2020
[3]. Age, sex, ethnicity, and the pre-existence of multiple
comorbidities have been recognised as factors associated
with prognosis in COVID-19 [1, 4, 5]. Frailty is also com-
mon among hospital inpatients with COVID-19 [6–8].
Frailty is a clinical state associated with older age and
characterised by an increased susceptibility to decom-
pensation in response to physiological stress [9]. While a
large number of measures have been used to identify
frailty, two operational definitions of frailty have domi-
nated the scientific literature on this field: the frailty
phenotype and the frailty index [10]. Using each of these
definitions, frailty has been associated with higher risk of
disability, morbidity, and mortality [11]. Several studies
have also reported a high prevalence of frailty in people
with chronic respiratory diseases [12–14], suggesting
that frailty may be an independent risk factor in the de-
velopment and progression of respiratory diseases [14].
One in four adults older than 85 years lives with frailty,
and according to a recent systematic review and meta-
analysis, one in six community-dwelling older adults
might have frailty [15]. Frailty is not, however, only associ-
ated with older age. Frailty and pre-frailty are higher
among those living with socioeconomic deprivation and
those with multimorbidity (≥ 2 long-term conditions
[LTCs]) even in middle-age [16].
During this pandemic, the clinical importance of frailty
is highlighted in clinical guidelines recommending frailty
assessment for all adults admitted to hospital [17, 18]. In
this context, frailty assessment is recommended as part of
a holistic approach to identifying patients in need of com-
prehensive geriatric assessment as well as identifying
people with the most severe frailty to guide consideration
of the appropriateness of critical care interventions. The
literature around COVID-19 and frailty is rapidly evolving,
and a number of hospital-based studies have demon-
strated that frailty is associated with greater risk of mortal-
ity and intensive-care admission with COVID-19 [7, 8,
19–21]. Most notably, the multi-centre COVID-19 in
Older People (COPE) study demonstrated that the Clin-
ical Frailty Scale was a better predictor of in-hospital death
than either age or comorbidity [19]. However, this associ-
ation with in-hospital mortality has not been consistently
observed across all studies to-date [7]. To our knowledge,
there have been no community-based studies on the asso-
ciation between frailty and risk of COVID-19 infection.
Therefore, this study aimed to compare the association
between frailty and severe COVID-19 infection resulting
in hospital admission or death in UK Biobank using two
different approaches to measuring frailty: the frailty
phenotype and the frailty index.
Methods
This study uses data from UK Biobank. Over 500,000 par-
ticipants (5.5% response rate), aged 37 to 73 years from
the general population, were recruited into UK Biobank
between March 2006 and December 2010 [22]. Partici-
pants attended one of 22 assessment centres across the
UK [23, 24] where they completed a touch-screen ques-
tionnaire, had physical measurements taken, and provided
biological samples, as described in detail elsewhere [23,
24]. For this study, only participants from English assess-
ment centres were included since data on COVID-19 sta-
tus of UK Biobank participants were only provided from
Public Health England (PHE) and no other parts of the
UK. Additionally, we excluded all participants known to
have died of non-COVID causes up to 16 March 2020.
Outcomes
PHE provided the COVID-19 test data, including the
specimen date, location, and result (positive or negative)
of the test. Data were available for the period 16 March
2020 to 28 June 2020. Records were also linked to in-
patient Hospital Episode Statistics and national mortality
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registers. From these, we identified individuals who
tested positive during an inpatient hospital episode, in
the 14 days prior to admission, or within 7 days of
hospital discharge. We also identified individuals who
had died with COVID-19 (ICD-10 code U70 on death
certification). Participants meeting this definition were
considered to have ‘severe COVID-19’ leading to hospi-
talisation or death. We compared these participants to
those who were alive during the pandemic but who had
not had an admission to hospital associated with
COVID-19.
More information on COVID-19 in UK Biobank can
be found here: http://biobank.ndph.ox.ac.uk/ukb/exinfo.
cgi?src=COVID19_tests.
Exposures: the frailty phenotype and the frailty index
We undertook our analyses using two different ap-
proaches to assessing frailty: the frailty phenotype and the
frailty index. Both frailty assessments were based on as-
sessment centre data collected at baseline (2006–2010).
An adapted version of the frailty phenotype derived by
Fried et al., and previously published using the UK Bio-
bank baseline data, was used in this study [16]. The
Fried phenotype uses the following five criteria: weight
loss, exhaustion, physical activity, walking speed, and
grip strength [25]. Some of these criteria were adapted
to fit the data available within UK Biobank [16].
Weight loss was derived from self-report of weight loss
in the previous year, dichotomised into yes or no (same
weight or gained weight). Exhaustion was derived from
the self-report of tiredness in the last 2 weeks cate-
gorised as follows: not at all, several days, more than half
the days, and nearly every day. Those participants who
reported tiredness more than half the days or nearly
every day were identified as meeting the Fried criterion
for exhaustion. Walking pace was categorised as slow,
average, or brisk. To derive a proxy for gait speed, this
was then dichotomised into slow or normal (average or
brisk pace). Grip strength was measured using a Jamar
J00105 hydraulic hand dynamometer. Isometric grip
force was assessed from a single 3-s maximal grip effort,
separately in the right and left arms, with the participant
seated upright with their elbow by their side and flexed
at 90° so that their forearm was facing forwards and rest-
ing on an armrest. The average of the right and left
values were expressed in absolute units (kg) and used in
subsequent analyses. Low grip strength was based on
cut-offs from Fried et al.’s original description, stratified
by sex and body mass index. Physical activity was self-
reported and classified as follows: none (response: none
or light activity with a frequency of once per week or
less = 1) and physically active (medium or heavy activity,
or light activity more than once per week = 0) [16].
Participants were classified as frail if they fulfilled three
or more criteria, pre-frail if they fulfilled one or two cri-
teria, and robust if they did not fulfil any criteria at base-
line. The three frailty groups were mutually exclusive.
A frailty index has previously been validated using
baseline data from UK Biobank [26]. The frailty index
approach was developed by Rockwood and Mitnitski
and is a cumulative count of ‘deficits’ [27, 28]. The frailty
index was initially described using 70 deficits from the
Canadian Study of Health Ageing [28]. However, the
frailty index method was developed as a standard tech-
nique which can be adapted to the deficits available in a
given dataset [29]. The adaptation of the frailty index ap-
proach to UK Biobank is described in detail elsewhere
[26]. Briefly, deficits should be associated with age, asso-
ciated with poor health status, and be neither universal
nor too rare within the target population [29]. A frailty
index is calculated for each individual by calculating the
total number of deficits present in an individual and di-
vided by the total number of possible deficits measurable
to give a value between 0 and 1 (higher values indicating
a greater degree of frailty). We applied a previously vali-
dated frailty index comprising 49 self-reported question-
naire items related to health, presence of disease and
disability, and mental wellbeing [26]. Based on this frailty
index, we classified participants as being robust (frailty
index < 0.12), mildly frail (frailty index 0.12–0.24), or
moderate/severely frailty (frailty index > 0.24) [30].
Covariates
Age at baseline was calculated from dates of birth and
baseline assessment. Current age was derived from dates of
birth and last data from COVID-19 assessment (June
2020). Area-based socioeconomic status (deprivation) was
derived from the postcode of residence, using the Town-
send score [31]. Ethnicity was self-reported and cate-
gorised, in this study, into white and non-white. This
approach was selected due to insufficient statistical power
in the non-white subgroups. Self-reported smoking status
was categorised as never, former, or current smoker. Fre-
quency of alcohol intake was self-reported at baseline via
touch-screen questionnaire and categorised as never/spe-
cial occasions only, 1–3 times per month, 1–4 times per
week, or daily/almost daily. Prevalent morbidity was ascer-
tained during a nurse-led interview at baseline. We calcu-
lated morbidity count based on 43 LTCs originally
developed for a large epidemiological study in Scotland
and subsequently adapted for UK Biobank [32, 33]. Further
details of these measurements can be found in the UK Bio-
bank online protocol (http://www.ukbiobank.ac.uk).
Ethical approval
UK Biobank was approved by the North West Multi-
Centre Research Ethics Committee (Ref: 11/NW/0382).
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All participants provided written informed consent to
participate in the UK Biobank study. The study protocol
is available online (http://www.ukbiobank.ac.uk). This
work was conducted under the UK Biobank application
number 14151.
Statistical analyses
Descriptive characteristics are presented as means with
standard deviations (SD) for quantitative variables and
as percentages for categorical variables, broken down by
each frailty classification and the presence or absence of
severe COVID-19 infection (defined as hospitalisation or
death with COVID-19). Poisson regression models with
robust standard errors were used to analyse the associa-
tions between both the frailty phenotype and the frailty
index and severe COVID-19. The results are reported as
risk ratios (RRs) with their 95% confidence intervals
(CIs) [34]. Poisson regression models with robust stand-
ard errors were used because they provide RR estimates,
instead of odds ratios, which are easier to interpret [35].
We ran four models including an increasing number
of covariates: model 1 (minimally adjusted), adjusted by
age and sex; model 2, as per model 1 but also included
deprivation, and white versus non-white groups; model
3, included smoking and alcohol intake only; and model
4, included all covariates in models 2 and 3. An add-
itional sensitivity analysis (model 5) was performed aim-
ing to investigate whether the association between the
frailty phenotype and COVID-19 was explained by mul-
timorbidity. This model included covariates in model 4,
but additionally included multimorbidity (based on a
count of 43 diseases and coded as ordinal 0, 1, 2, 3, and
≥ 4 LTCs). This model was carried out for the frailty
phenotype only because the frailty index is partly based
on the presence of morbidity. All these covariates were
selected because they have been recognised as being as-
sociated with prognosis of COVID-19 as well as being
associated with frailty status, and may therefore poten-
tially confound the relationship between frailty and
COVID-19 [1, 4, 5].
Finally, to investigate whether the associations between
severe COVID-19 and frailty differed by subgroups, the
analyses were re-run stratified by sex and age categories
(based on age in June 2020: < 60, 60–70, and > 70 years).
An interaction term among the subgroups, the frailty
classifications, and severe COVID-19 was fitted into the
regression model to test for interaction.
All statistical analyses were performed using R version
3.6.1. Only participants with full data available for both
classifications and covariates were included in the analyses.
Results
A total of 420,577 UK Biobank participants in England
were eligible for inclusion, of whom 383,845 had data on
both frailty phenotype and frailty index. Of these, 802
were either hospitalised with and/or died from COVID-
19 and were classified as ‘severe COVID-19’ (323 deaths
and 479 hospitalisations only). The proportion of people
identified as frail at baseline, along with the overlap be-
tween the frailty phenotype and the frailty index, is
shown in Table 1. Out of 383,845 participants, 11,836
(3.1%) participants were frail according to the frailty
phenotype, and 15,958 (4.1%) had moderate or severe
frailty according to the frailty index. Using the frailty
phenotype, and compared with robust individuals, pre-
frail and frail individuals with severe COVID-19 were
older, more likely to be deprived, non-white, current
smoker, to never or occasionally drink alcohol, and to
have one or more morbidities (Table 2). Similar charac-
teristics were identified when individuals with mild
frailty and moderate/severe frailty were compared with
robust individuals using the frailty index (Table S1).
Associations between the frailty phenotype and the
frailty index and severe COVID-19 are presented in
Fig. 1. Using the frailty phenotype, and compared
with non-frail individuals, being pre-frail and frail
were associated with 1.69 times [95% CI 1.46; 1.96]
and more than four times [RR 4.05 95% CI 3.15;
5.20] higher risk of severe COVID-19, respectively
(age- and sex-adjusted model). These associations
were attenuated but remained when analyses were ad-
justed both for sociodemographic and lifestyle factors
(RRpre-frail 1.47 [95% CI 1.26; 1.71] and RRfrail 2.66
[95% CI 2.04; 3.47]) (model 4, Fig. 1). Results were
similar in analyses using the frailty index, although ef-
fect sizes were slightly smaller. In the age- and sex-
adjusted model, individuals with mild frailty and mod-
erate/severe frailty had 1.73 [95% CI 1.49; 2.00] and
3.56 [95% CI 2.82; 4.48] times higher risk of severe
COVID-19, respectively, compared with robust indi-
viduals. When we further adjusted the model for
sociodemographic and lifestyle factors, the associa-
tions attenuated further, but remained (RRmild-frail
1.46 [95% CI 1.26; 1.71] and RRmod/severe frail 2.43
[95% CI 1.91; 3.10]) (model 4, Fig. 1). In addition,
when multimorbidity was included in the sensitivity
analysis for the frailty phenotype only (Table S2,
model 5), the associations remained but were further
attenuated (RRpre-frail 1.35 [95% CI 1.16; 1.57] and
RRfrail 1.99 [95% CI 1.51; 2.62]).
For the frailty index, we repeated model 4 treating the
frailty index as continuous. There was a RR of 1.53 (95%
CI 1.40; 1.67) per 0.1-point increase in the frailty index.
No significant interaction was observed between either
frailty definition and age or sex (Fig. 2). When the ana-
lyses were stratified by subgroups (sex and age categor-
ies), we identified that the associations were similar for
both sexes and age categories using both the frailty
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index and the frailty phenotype (Fig. 2). However, the ef-
fect of frailty using the frailty phenotype was higher in
people aged < 60 at the time of the pandemic (Fig. 2).
Discussion
We demonstrated that people previously identified as
frail were at higher risk of severe COVID-19 infection,
after adjustment for sociodemographic and lifestyle fac-
tors and independent of multimorbidity in the case of
the frailty phenotype. These findings were consistent
using two different approaches to assessing frailty: the
frailty phenotype and the frailty index.
Attenuation following adjustment for multimorbidity
using the frailty phenotype is to be expected since mor-
bidity contributes to frailty: 91.9% of frail individuals
with severe COVID-19 had multimorbidity versus 75.6%
of those classified as robust. On the other hand, we iden-
tified that the associations were similar after
Table 1 Overlap between the frailty phenotype and frailty index
Robust, n (%) Mild, n (%) Moderate or severe, n (%) Total
Robust, n (%) 170,964 (44.5) 55,456 (14.5) 2665 (0.7) 229,085 (59.7)
Pre-frail, n (%) 75,898 (19.8) 57,719 (15.0) 9307 (2.4) 142,924 (37.2)
Frail, n (%) 1770 (0.5) 6080 (1.6) 3986 (1.0) 11,836 (3.1)
Total 248,632 (64.8) 119,255 (31.1) 15,958 (4.1) 383,845
Data presented as absolute numbers and prevalence for each frailty measurement
Table 2 Characteristics of the population according to their COVID-19 test and the frailty phenotype
No COVID-19 associated admission or death Severe COVID-19 infection
Robust Pre-frail Frail Robust Pre-frail Frail
Total, n 228,731 142,550 11,762 354 374 74
Baseline age (years), mean (SD) 56.0 (8.1) 56.5 (8.1) 57.4 (7.7) 60.3 (7.7) 59.8 (7.8) 59.5 (7.9)
Current age (years), mean (SD) 67.1 (8.1) 67.5 (8.1) 68.4 (7.7) 71.3 (7.8) 70.8 (7.8) 70.6 (8.0)
Sex (female), n (%) 120,231 (52.6) 83,011 (58.2) 7772 (66.1) 116 (32.8) 145 (38.8) 35 (47.3)
Deprivation, n (%)
Lower 83,333 (36.5) 42,368 (29.7) 2086 (17.7) 92 (26.0) 87 (23.3) 9 (12.1)
Middle 78,557 (34.3) 46,199 (32.4) 2947 (25.1) 123 (34.7) 95 (25.4) 15 (20.3)
Higher 66,841 (29.2) 53,983 (37.9) 6729 (57.2) 139 (39.3) 192 (51.3) 50 (67.6)
Ethnicity, n (%)
White 220,508 (96.4) 132,223 (92.8) 10,204 (86.8) 325 (91.8) 324 (86.6) 63 (85.1)
Non-white 8223 (3.6) 10,327 (7.2) 1558 (13.2) 29 (8.2) 50 (13.4) 11 (14.9)
Smoking status, n (%)
Never 130,457 (57.0) 76,966 (54.0) 5737 (48.8) 134 (37.9) 177 (47.3) 25 (33.8)
Previous 79,074 (34.6) 49,909 (35.0) 4021 (34.2) 173 (48.9) 151 (40.4) 37 (50.0)
Current 19,200 (8.4) 15,675 (11.0) 2004 (17.0) 47 (13.2) 46 (12.3) 12 (16.2)
Alcohol intake, n (%)
Daily or almost daily 53,467 (23.4) 25,316 (17.8) 1176 (10.0) 77 (21.8) 62 (16.6) 9 (12.2)
One to four times a week 119,836 (52.4) 66,267 (46.5) 3711 (31.6) 172 (48.6) 147 (39.3) 24 (32.4)
One to three times a month 23,582 (10.3) 17,695 (12.4) 1487 (12.6) 40 (11.2) 43 (11.5) 10 (13.5)
Never or special occasions 31,846 (13.9) 33,272 (23.3) 5388 (45.8) 65 (18.4) 122 (32.6) 31 (41.9)
Multimorbidity, n (%)
None 93,868 (41.0) 40,383 (28.4) 1068 (9.1) 87 (24.6) 65 (17.4) 6 (8.1)
1 78,185 (34.2) 46,384 (32.5) 2357 (20.0) 119 (33.6) 106 (28.3) 7 (9.5)
2–3 51,407 (22.5) 46,373 (32.5) 5371 (45.7) 133 (37.6) 156 (41.7) 36 (48.6)
≥ 4 5271 (2.3) 9410 (6.6) 2966 (25.2) 15 (4.2) 47 (12.6) 25 (33.8)
The frailty phenotype was derived using an adaptation from the original derived by Fried et al. Participants were classified as frail if they fulfilled three or more
criteria, pre-frail if they fulfilled one or two criteria, and robust if they did not fulfil any criteria at baseline
SD standard deviation, n number
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Fig. 1 Associations between the frailty phenotype, the frailty index, and severe COVID-19 infection. Data presented as RRs with their 95% CIs
using Poisson regression analyses. Robust individuals were used as the reference group for the frailty phenotype and the frailty index. Model 1,
adjusted by age and sex; model 2, as model 1 but also included deprivation, and ethnicity: white versus others; model 3, included smoking and
alcohol intake only; model 4, included the covariates in models 2 and 3
Fig. 2 Associations between the frailty phenotype, the frailty index, and severe COVID-19 infection by subgroups. Data presented as RRs with
their 95% CIs using Poisson regression analyses. Robust individuals were used as the reference group for the frailty phenotype and the frailty
index. All the analyses were adjusted by age, sex, deprivation, ethnicity, smoking, and alcohol intake when these were not the subgroup used
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stratification by sex and age (except for some exceptions
probably underpowered). The latter highlights the im-
pact of our findings but also reinforces the implications
of frailty beyond ageing [16].
Frailty (either moderate or severe) has been identified
among inpatients affected by COVID-19 [6–8, 19–21].
This is consistent with previous findings where frailty
has been recognised as a critical prognostic factor of
viral pneumonia among inpatients [13]. However, the lit-
erature has reported heterogeneous results between
frailty and COVID-19 mortality. For example, Miles
et al., using data from 377 older inpatients admitted to a
London hospital, identified that frailty was not associ-
ated with mortality rates after COVID-19 [7]. However,
Hewitt et al. and De Smet et al., using the Clinical Frailty
Scale (CFS), demonstrated that frail individuals had a
higher risk of mortality after adjusting for covariates [19,
20]. Our study is novel since it demonstrates an in-
creased risk of hospitalisation or death from COVID-19
among community-dwelling individuals, but does not in-
vestigate prognosis after hospitalisation.
As with COVID-19, frailty is strongly associated with
ageing. It also shares some common modifiable risk fac-
tors with COVID-19, such as body mass index, muscle
strength, respiratory function, and slow gait speed [4,
36]. Although chronological age cannot be modified, key
proxies of physical function related to ageing and frailty
can. There is evidence that frailty could be reversed with
exercise interventions in some older adults [37]. A re-
cent trial conducted in hospitalised frail individuals
showed that an exercise intervention was effective at
helping to reverse the functional decline associated with
ageing [38]. Therefore, there is a need to recognise frail
individuals as a higher risk group and determine how
best to balance their competing risks, providing greater
protection from infection through existing non-
pharmaceutical interventions such as physical distancing
and shielding, while encouraging and supporting greater
physical activity to reduce their frailty. This could poten-
tially be achieved through home training programmes
for people with restriction of mobility [39], and perhaps
drawing upon the intersection between frailty and re-
spiratory disease [40, 41]. Of note, interventions that
prevent, delay, or reverse frailty are likely to have signifi-
cant public health impact beyond the COVID-19.
Limitations
This study is not without limitations. Firstly, both the
frailty phenotype and the frailty index were identified
from baseline UK Biobank data (between 10 and 14 years
prior to the COVID-19 pandemic). Therefore, we did
not have data on subsequent frailty status. Frailty is a dy-
namic state and is likely to have worsened over time.
Consequently, transitioning from a frail to a less frail
state is relatively uncommon; however, a proportion of
those not identified as frail at baseline are likely to have
become frail during the follow-up [42]. Therefore, our
results may be an underestimate of the magnitude of the
association between frailty and COVID-19. Secondly,
while the frailty phenotype and the frailty index are the
most widely validated epidemiological measurements of
frailty, they are not routinely used within clinical prac-
tice. NICE (National Institute for Health and Care Excel-
lence) has recommended using the CFS for the
assessment of frailty in the COVID-19 guideline [17].
However, due to the absence of some of the variables in-
cluded in the CFS in the UK Biobank study, we used a
frailty index [26] and an adapted version of the frailty
phenotype [16]. While there appears to be a modest de-
gree of overlap between the CFS and other frailty defini-
tions [43], few studies have assessed in detail how the
CFS related to measures such as the frailty index or
frailty phenotype. The frailty phenotype was an adapta-
tion of the original description by Fried et al. [25], and
the frailty index was derived from self-reported data
only. Finally, the UK Biobank study is not a nationally
representative sample in terms of lifestyle, morbidity,
ethnicity, and socioeconomic status [44]. This lack of
representativeness is an important limitation, particu-
larly as characteristics such as ethnicity and comorbidi-
ties appear to be strongly associated with prognosis in
COVID-19 [45]. Therefore, the summary statistics
should not be generalised [44], even though effect size
estimates are comparable with nationally representative
cohorts [46].
Conclusion
Individuals with frailty had a higher risk of severe
COVID-19 regardless of the frailty measure used. As
the lockdown measures have changed during the
course of the pandemic, guidance on how we can
protect individuals with frailty should be considered,
including whether more protective, preventive mea-
sures are required. Moreover, considering we are fa-
cing a new COVID-19 outbreak and that confinement
could exacerbate frailty [47], further public health
policies to minimise the risk of developing this syn-
drome are more urgent than ever.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01822-4.
Additional file 1: Table S1. Characteristics of the population according
to their COVID-19 test and the frailty index. Table S2. Associations be-
tween the frailty phenotype and severe COVID-19 infection (sensitivity
analysis).
Petermann-Rocha et al. BMC Medicine          (2020) 18:355 Page 7 of 9
Abbreviations
CFS: Clinical Frailty Scale; CIs: Confidence intervals; FI: Frailty index;
LTCs: Long-term conditions; NICE: National Institute for Health and Care
Excellence; PHE: Public Health England; RR: Risk ratio; SARS-CoV-2: Severe
acute respiratory syndrome coronavirus 2
Acknowledgements
This research has been conducted using the UK Biobank resource. We are
grateful to UK Biobank participants.
Authors’ contributions
F.P-R, P.H, B.I.N, J.P.P, B.D.J, F.K.H, F.S.M, and C.C-M contributed to the
conception and design of the study, advised on all statistical aspects, and
interpreted the data. F.P-R and P.H performed the literature search. P.H
performed the analyses. All authors critically reviewed this and previous
drafts. All authors approved the final draft for submission. F.P-R and P.H
contributed equally to this work and are joint first authors. B.I.N, J.P.P, B.D.J,
F.K.H, F.S.M, and C.C-M contributed equally to this work and are joint senior
authors. C.C-M is the guarantor.
Funding
UK Biobank was established by the Wellcome Trust medical charity, Medical
Research Council, Department of Health, Scottish Government, and
Northwest Regional Development Agency. It has also had funding from the
Welsh Assembly Government and the British Heart Foundation. All authors
had final responsibility for submission for publication. F.P-R receives financial
support from the Chilean Government for doing her PhD (ANID-Becas Chile
2018 – 72190067). P.H was funded by a Medical Research Council Clinical
Research Training Fellowship MR/S021949/1.
Availability of data and materials
All UK Biobank information is available online on the webpage www.
ukbiobank. Data access is available through applications. This research was
conducted using the application number 14151.
Ethics approval and consent to participate
UK Biobank was approved by the North West Multi-Centre Research Ethics
Committee, and all participants provided written informed consent to partici-
pate in the UK Biobank study. The study protocol is available online (http://
www.ukbiobank.ac.uk/).
Consent for publication
Non-applicable.
Competing interests
The authors declare no conflicts of interest.
Author details
1Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
2British Heart Foundation Glasgow Cardiovascular Research Centre, Institute
of Cardiovascular and Medical Sciences, College of Medical, Veterinary and
Life Sciences, University of Glasgow, Glasgow G12 8TA, UK. 3Centre of
Exercise Physiology Research (CIFE), Universidad Mayor, Santiago, Chile.
4Laboratorio de Rendimiento Humano, Grupo de Estudio en Educación,
Actividad Física y Salud (GEEAFyS), Universidad Católica del Maule, Talca,
Chile.
Received: 2 June 2020 Accepted: 20 October 2020
References
1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L,
Holden KA, Read JM, Dondelinger F, Carson G, et al. Features of 20 133 UK
patients in hospital with covid-19 using the ISARIC WHO Clinical
Characterisation Protocol: prospective observational cohort study. BMJ.
2020;369:m1985.
2. Landi F, Barillaro C, Bellieni A, Brandi V, Carfì A, D'Angelo M, Fusco D, Landi
G, Lo Monaco R, Martone AM, et al. The new challenge of geriatrics: saving
frail older people from the SARS-COV-2 pandemic infection. J Nutr Health
Aging. 2020;24(5):466–70.
3. Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed 27 Oct 2020.
4. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C,
Lyall DM, Ferguson LD, Berry C, Mackay DF et al: Modifiable and non-
modifiable risk factors for COVID-19: results from UK Biobank. medRxiv 2020:
2020.2004.2028.20083295.
5. Niedzwiedz CL, O'Donnell CA, Jani BD, Demou E, Ho FK, Celis-Morales C,
Nicholl BI, Mair F, Welsh P, Sattar N: Ethnic and socioeconomic differences
in SARS-CoV-2 infection: prospective cohort study using UK Biobank.
medRxiv. BMC Med. 2020;18(1):160.
6. Turner J, Eliot Hodgson L, Leckie T, Eade L, Ford-Dunn S. A dual-center
observational review of hospital-based palliative care in patients dying with
COVID-19. J Pain Symptom Manag. 2020;60(2):e75–8.
7. Miles A, Webb TE, McLoughlin BC, Mannan I, Rather A, Knopp P, Davis D.
Outcomes from COVID-19 across the range of frailty: excess mortality in
fitter older people. Eur Geriatr Med. 2020;11(5):851–5.
8. Maltese G, Corsonello A, Di Rosa M, Soraci L, Vitale C, Corica F, Lattanzio F:
Frailty and COVID-19: a systematic scoping review. J Clin Med. 2020;9(7):2106.
9. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people.
Lancet. 2013;381(9868):752–62.
10. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications
for clinical practice and public health. Lancet. 2019;394(10206):1365–75.
11. Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr
Med. 2011;27(1):1–15.
12. Johnston K, Patel B, Trojak R, Adebajo B, Akinlabi K. Frailty in chronic
respiratory disease: prevalence and comparison of rehabilitation clinical
outcomes. Eur Respir J. 2019;54(suppl 63):PA575.
13. Falcone M, Blasi F, Menichetti F, Pea F, Violi F. Pneumonia in frail older
patients: an up to date. Intern Emerg Med. 2012;7(5):415–24.
14. Guan C, Niu H. Frailty assessment in older adults with chronic obstructive
respiratory diseases. Clin Interv Aging. 2018;13:1513–24.
15. Ofori-Asenso R, Chin KL, Mazidi M, Zomer E, Ilomaki J, Zullo AR, Gasevic D,
Ademi Z, Korhonen MJ, LoGiudice D, et al. Global incidence of frailty and
prefrailty among community-dwelling older adults: a systematic review and
meta-analysis. JAMA Netw Open. 2019;2(8):e198398.
16. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-
frailty in middle-aged and older adults and its association with
multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank
participants. Lancet Public Health. 2018;3(7):e323–32.
17. COVID-19 rapid guideline: critical care in adults. https://www.nice.org.uk/
guidance/ng159. Accessed 31 Aug 2020.
18. COVID-19 position statement: Presentations and management of COVID-19
in older people in acute care. https://www.sign.ac.uk/assets/sg_
presentations_and_management_of-covid-19_in_older_people.pdf.
Accessed 31 Aug 2020.
19. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, Pearce L,
Stechman M, Short R, Price A, et al. The effect of frailty on survival in
patients with COVID-19 (COPE): a multi-centre, European, observational
cohort study. Lancet Public Health. 2020;5(8):e444–51.
20. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S,
Lemahieu W, Symons R, Ho E, Frans J, et al. Frailty and mortality in
hospitalized older adults with COVID-19: retrospective observational study. J
Am Med Dir Assoc. 2020;21(7):928–932.e921.
21. Bellelli G, Rebora P, Valsecchi MG, Bonfanti P, Citerio G. Frailty index predicts
poor outcome in COVID-19 patients. Intensive Care Med. 2020;46(8):1634–6.
22. Collins R. What makes UK Biobank special? Lancet (London). 2012;
379(9822):1173–4.
23. Palmer LJ. UK Biobank: bank on it. Lancet (London). 2007;369(9578):1980–2.
24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
P, Green J, Landray M, et al. UK biobank: an open access resource for
identifying the causes of a wide range of complex diseases of middle and
old age. Plos Med. 2015;12(3):e1001779.
25. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J,
Seeman T, Tracy R, Kop WJ, Burke G, et al. Frailty in older adults: evidence
for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.
26. Williams DM, Jylhävä J, Pedersen NL, Hägg S. A frailty index for UK Biobank
participants. J Gerontol A Biol Sci Med Sci. 2019;74(4):582–7.
27. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy
measure of aging. ScientificWorldJournal. 2001;1:323–36.
28. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J
Gerontol A Biol Sci Med Sci. 2007;62(7):722–7.
29. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard
procedure for creating a frailty index. BMC Geriatr. 2008;8(1):24.
Petermann-Rocha et al. BMC Medicine          (2020) 18:355 Page 8 of 9
30. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, Mohammed MA,
Parry J, Marshall T. Development and validation of an electronic frailty index
using routine primary care electronic health record data. Age Ageing. 2016;
45(3):353–60.
31. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and
the North. London: Croom Helm; 1987.
32. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
of multimorbidity and implications for health care, research, and medical
education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
33. Nicholl BI, Mackay D, Cullen B, Martin DJ, Ul-Haq Z, Mair FS, Evans J,
McIntosh AM, Gallagher J, Roberts B. Chronic multisite pain in major
depression and bipolar disorder: cross-sectional study of 149,611
participants in UK Biobank. BMC psychiatry. 2014;14(1):350.
34. Zou G. A modified poisson regression approach to prospective studies with
binary data. Am J Epidemiol. 2004;159(7):702–6.
35. Grant RL. Converting an odds ratio to a range of plausible relative risks for
better communication of research findings. BMJ. 2014;348:f7450.
36. Hamer M, Kivimäki M, Gale CR, David Batty G: Lifestyle risk factors,
inflammatory mechanisms, and COVID-19 hospitalization: a community-based
cohort study of 387,109 adults in UK. Brain, Behav Immun. 2020;87:184–7.
37. Travers J, Romero-Ortuno R, Bailey J, Cooney M-T. Delaying and reversing
frailty: a systematic review of primary care interventions. Br J Gen Pract.
2019;69(678):e61–9.
38. Tarazona-Santabalbina FJ, Gómez-Cabrera MC, Pérez-Ros P, Martínez-Arnau
FM, Cabo H, Tsaparas K, Salvador-Pascual A, Rodriguez-Mañas L, Viña J. A
multicomponent exercise intervention that reverses frailty and improves
cognition, emotion, and social networking in the community-dwelling frail
elderly: a randomized clinical trial. J Am Med Dir Assoc. 2016;17(5):426–33.
39. Jiménez-Pavón D, Carbonell-Baeza A, Lavie CJ. Physical exercise as
therapy to fight against the mental and physical consequences of
COVID-19 quarantine: special focus in older people. Prog Cardiovasc
Dis. 2020;63(3):386–8.
40. Maddocks M, Kon SS, Canavan JL, Jones SE, Nolan CM, Labey A, Polkey MI,
Man WD. Physical frailty and pulmonary rehabilitation in COPD: a
prospective cohort study. Thorax. 2016;71(11):988–95.
41. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in
elderly patients with COVID-19: a randomized controlled study.
Complement Ther Clin Pract. 2020;39:101166.
42. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty
states among community-living older persons. Arch Intern Med. 2006;
166(4):418–23.
43. Theou O, Brothers TD, Mitnitski A, Rockwood K. Operationalization of frailty
using eight commonly used scales and comparison of their ability to
predict all-cause mortality. J Am Geriatr Soc. 2013;61(9):1537–51.
44. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R,
Allen NE. Comparison of sociodemographic and health-related
characteristics of UK biobank participants with those of the general
population. Am J Epidemiol. 2017;186(9):1026–34.
45. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis
HJ, Mehrkar A, Evans D, Inglesby P, et al. Factors associated with COVID-19-
related death using OpenSAFELY. Nature. 2020;584(7821):430–6.
46. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor
associations in UK Biobank against representative, general population based
studies with conventional response rates: prospective cohort study and
individual participant meta-analysis. BMJ. 2020;368:m131.
47. Xu S, Li Y. Beware of the second wave of COVID-19. Lancet. 2020;
395(10233):1321–2.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Petermann-Rocha et al. BMC Medicine          (2020) 18:355 Page 9 of 9
